Effect of Ezetimibe on visceral fat suppression in patients with chronic liver disease and hyperlipidemia ; a randomized, double blind, placebo-controlled, clinical trial

Phase 2

• Conditions: chronic liver disease with hyperlipidemia

• Registration Number: JPRN-UMIN000005540
• Lead Sponsor: Yokohama City University Medical Center Gastroenterological Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-05-02
• Study Completion: 2012-05-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

Not provided

Exclusion Criteria

1.Subjects during pregnancy, feeding, intimation of pregnancy or intended pregnancy 2.Subjects who have already treated with interferon and ribavirin 3.Subjects who have already treated with steroids, immunosuppressive agent, and antitumor agent. 4.Other,Subjects deemed unsuitable for the doctor

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The change in visceral fat (measured by helical CT scan)

Secondary Outcome Measures

Name	Time	Method
1)The change in serum viral genome every four weeks 2)The change in serum lipid or lipid marker levels 3)The change in serum ALT 4)The analysis of Liver tissue and lipid marker level